Dr. Alan Tan explores circulating tumor DNA, its role in clinical trials and its potential impact on patients with renal cell carcinoma.

Survival is good for patients when renal cell carcinoma (RCC) is caught early, but options for advanced disease present challenges, explained Alan Tan, MD, an assistant professor in the Division of ...

Many times, renal cell carcinoma (RCC) is found incidentally, as a result of something else, said Alan Tan, MD, an assistant professor in the Division of Hematology, Oncology and Cell Therapy at Rush ...

Circulating tumor DNA (ctDNA) is emerging as a promising biomarker to predict treatment response in patients with metastatic renal cell carcinoma (mRCC). In a recent study, Alan Tan, MD, of Vanderbilt ...

Alan Tan is an adjunct lecturer in the information systems & analytics department since September 2015. He instructs graduate students in classes related to E-Business Technologies and Virtualization.